Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK)
G. Dranitsaris, M. Lidgren, J. Lundkvist, R. ColemanVolume:
6
Year:
2008
Language:
english
DOI:
10.1016/s1359-6349(08)70374-4
File:
PDF, 60 KB
english, 2008